DTP3 TFA 产品活性：DTP3 TFA 是一种有效且选择性的 GADD45β/MKK7 抑制剂。DTP3 TFA 靶向 NF-κB 途径下游，具有抗癌活性。 产品来源： https://www.medchemexpress.cn/dtp3-tfa.html 研究领域：Cell Cycle/DNA Damage | MAPK/ERK Pathway 作用靶点：DNA/RNA Synthesis | JNK In Vitro: DTP3 (10 μM; 1-21 days) causes the potent and tumor-selective induction of JNK activation and apoptosis, as shown by the appearance of phosphorylated JNK, as early as 24 hours. In Vivo: DTP3 TFA (s.c.; 14.5 mg/kg/day; 28 days) has shown a dramatic shrinkage of the tumors, and virtually eradicates established subcutaneous myeloma xenografts in mice. DTP3 TFA (intravenous injection; 10 mg/kg/day) has t1/2 of 1.26 hours, CL of 27.13 ML/min/kg, and Vd of 2.80 L/kg. 相关产品：Cycloheximide | Actinomycin D | Oxaliplatin | Gemcitabine | SP600125 | Bleomycin sulfate | Carboplatin | Mitomycin C | Cytarabine | 5-BrdU | Methotrexate | Streptozotocin | Anisomycin | Fludarabine | ART558 | Propidium Iodide | Thymidine | Hydroxyurea | Daunorubicin hydrochloride | Remdesivir | Capecitabine | JNK-IN-8 | Brequinar | Urolithin A | Folic acid | CX-5461 | Chloramphenicol | α-Amanitin 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。